Markets
Exelixis Stock Soars 9%, Adding $1.4 Billion, After Cabozantinib Sales Lift Quarterly Revenue
The cancer drugmaker kept its 2026 revenue range, cut its expected tax rate and hit a 52-week high of $71.83 on Friday.
EXEL
Exelixis (EXEL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Exelixis Says FDA Action Date For Zanzalintinib Is March 3, 2027, With Kidney Data Due In First Quarter
Executives set two dates for the drug meant to be the company's second franchise, and shut down questions about talks with the agency.
Earnings
Exelixis Keeps Its 2026 Revenue Outlook Even As Cabometyx Sales Grow About 6% From The Prior Quarter
The CFO said the slower neuroendocrine build behind last quarter's guidance cut "continues today," while the company bought back about $250 million of stock.
Earnings
Exelixis Spent $1 Billion On Buybacks In Nine Months, Far More Than Its $640.6 Million Profit
Per-share earnings are climbing as the share count shrinks, while cash fell and a rival cabozantinib product won full FDA approval.
SEC Filings
Exelixis Lifts Quarterly Revenue To $658.7 Million, Cuts Tax-Rate Outlook To 16%-18%
The cancer drugmaker held its 2026 revenue range at $2.500 billion to $2.550 billion while lowering its expected tax rate.